Price target was C$.85 IF ATB-346 was approved but that's not likely before 2020
A little more than a double doesn't seem like much potential upside to what could be a blockbuster drug. What are your thoughts regarding that valuation? If it seems legit than it certainly would make sense to take some profits given the risk & time.